Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2015 | editorial

American Society of Clinical Oncology annual meeting 2015

verfasst von: Wolfgang Eisterer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Excerpt

The annual meeting of the American Society of Clinical Oncology represents the yearly highlight for the world-wide oncologic community. This year saw around 30,000 participants convening in Chicago where they were presented with a wealth of new data. …
Vorheriger Artikel Obituary for Dr. Ferdinand Ploner
Nächster Artikel Biomarkers—hope and hype
Literatur
1.
Spigel DR, Reckamp KL, Rizvi NA, et al. A phase III study (Checkmate 017) of nivolumab (NIVO; anti-programmed death 1 (PD-1)) vs docetaxel (DOC) in previously treated advanced or metastaic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. (suppl;abstr 8009).
2.
Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433–43.PubMedCrossRef
3.
Ellis P, Barrios CH, Eiermann W, et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J Clin Oncol. 2015;33. (suppl; abstr 507).
4.
Bang YJ, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33. (suppl; abstr 4001).
5.
Cunningham D, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. 2015;33. (suppl; abstr 4000).
6.
Pavlakis N, et al. INTEGRATE. A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. J Clin Oncol. 2015;33. (suppl 3; abstr 9).
7.
Tapp WD. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). J Clin Oncol. 2015;33. (suppl; abstr 10501).
8.
Mir O. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.,). J Clin Oncol. 2015;33. (suppl; abstr 10504).
9.
Kim C. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma). J Clin Oncol. 2015;33. (suppl; abstr 10565).
10.
Burgess MA. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.,). J Clin Oncol. 2015;33. (suppl; abstr TPS10578).
11.
Demetri GD. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). J Clin Oncol. 2015;33. (suppl; abstr 10503).
12.
Schoeffski P. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).). J Clin Oncol. 2015;33. (suppl; abstr 10542).
13.
Joensuu H. Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial). J Clin Oncol. 2015;33. (suppl; abstr 10505).
14.
Chandrajit PR. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.,). J Clin Oncol. 2015;33. (suppl; abstr 10537).
15.
Blay JY. Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).). J Clin Oncol. 2015;33. (suppl; abstr 10506).
16.
Le DTL, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33. (suppl; abstr LBA 100). Late Breaking Abstract 100.
17.
Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.). J Clin Oncol. 2015;33. (suppl; abstr 3508).
18.
Ruers T, Punt CJA, van Coevorden F, et al. Radiofrequency ablation combined with chemotherapy for unresectable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).). J Clin Oncol. 2015;33. (suppl; abstr 3501).
19.
Gibbs P, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 ± selective internal radiation therapy ± bevacizumab in patients with metastatic colorectal cancer.). J Clin Oncol. 2015;33. (suppl; abstr 3502).
Metadaten
Titel
American Society of Clinical Oncology annual meeting 2015
verfasst von
Wolfgang Eisterer, MD
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0236-2

Weitere Artikel der Ausgabe 4/2015

Malignant pleural effusion: pathogenesis, diagnosis, and management

  • review

Giant Merkel cell carcinoma of the face, immediate results after radiation therapy: a case report and review of the literature

  • case report

Thermoablation: a new treatment option to replace surgical intervention?

  • short review

ASCO update 2015: lung cancer

  • short review

Biomarkers—hope and hype

  • editorial

Exosomes as novel biomarkers in anticancer therapy

  • short review